Galmed Pharmaceuticals Ltd.
EOCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595353
No open-market purchases or sales by Galmed Pharmaceuticals Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $85.9K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Galmed Pharmaceuticals Ltd. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- −2 vs. Q1 2026
- Shares held
- 155.7K
- +9.95K (+6.8%) vs. Q1 2026
- Total value
- $85.9K
- +$14.7K (+20.7%) vs. Q1 2026
- New holders
- 2
- 2 more added
- Sold out
- 4
- 4 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EOCN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 14 | $85.9K |
| Q1 2026 | 16 | $71.2K |
| Q4 2025 | 17 | $166.4K |
| Q3 2025 | 14 | $102.0K |
| Q2 2025 | 15 | $140.2K |
| Q1 2025 | 13 | $80.4K |
| Q4 2024 | 12 | $142.8K |
| Q3 2024 | 10 | $38.3K |
| Q2 2024 | 13 | $112.9K |
| Q1 2024 | 13 | $57.6K |
| Q4 2023 | 14 | $248.8K |
| Q3 2023 | 17 | $428.2K |
| Q2 2023 | 12 | $419.1K |
| Q1 2023 | 21 | $878.3K |
| Q4 2022 | 22 | $1.21M |
| Q3 2022 | 25 | $803.6K |
| Q2 2022 | 22 | $1.70M |
| Q1 2022 | 23 | $4.47M |
| Q4 2021 | 24 | $7.05M |
| Q3 2021 | 26 | $11.8M |
| Q2 2021 | 25 | $14.6M |
| Q1 2021 | 30 | $19.4M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Galmed Pharmaceuticals Ltd.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| TSFG, LLC | 17 | $0 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 550 | $0 | 0.00% | +550 | New |
| ZRC Wealth Management, LLC | 1 | $1 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 3 | $2 | 0.00% | −2,543−99.9% | Reduced |
| Advisor Group Holdings, Inc. | 5 | $2 | 0.00% | 00.0% | Unchanged |
| Allworth Financial LP | 2 | $2 | 0.00% | 00.0% | Unchanged |
| Federation des caisses Desjardins du Quebec | 14 | $8 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 43 | $24 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 56 | $31 | 0.00% | −101−64.3% | Reduced |
| SBI Securities Co., Ltd. | 66 | $37 | 0.00% | +50+312.5% | Added |
| Two Sigma Securities, LLC | 11,012 | $6.13K | 0.00% | −959−8.0% | Reduced |
| XTX Topco Ltd | 15,015 | $8.35K | 0.00% | −7,381−33.0% | Reduced |
| HRT Financial LP | 42,090 | $23.0K | 0.00% | +42,090 | New |
| Citadel Advisors LLC | 86,851 | $48.3K | 0.00% | +75,469+663.1% | Added |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −80,177−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −16,445−100.0% | Sold out |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −600−100.0% | Sold out |
| Dogwood Wealth Management LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |